|
ITEM 1.
|
CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS.
|
ALR TECHNOLOGIES
INC.
Condensed Consolidated
Financial Statements
June 30,
2021 and 2020
(unaudited)
Index
|
Page
|
|
|
Condensed Consolidated Balance Sheets
|
4
|
|
|
Condensed Consolidated
Statements of Operations
|
5
|
|
|
Condensed Consolidated
Statements of Cash Flows
|
6
|
|
|
Notes to Condensed
Consolidated Financial Statements
|
7 – 21
|
ALR TECHNOLOGIES INC.
Condensed Consolidated Balance Sheets
($ United States)
|
|
|
|
|
|
|
June 30,
2021
|
|
December 31,
2020
|
|
|
|
(unaudited)
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
376,639
|
|
|
$
|
66,190
|
|
Prepaid expenses
|
|
|
57,556
|
|
|
|
62,659
|
|
Total assets
|
|
$
|
434,195
|
|
|
$
|
128,849
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Deficit
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
937,270
|
|
|
$
|
1,113,720
|
|
Promissory notes payable to related parties
|
|
|
3,031,966
|
|
|
|
3,031,966
|
|
Promissory notes payable to unrelated parties
|
|
|
2,223,368
|
|
|
|
2,254,353
|
|
Interest payable
|
|
|
3,847,411
|
|
|
|
3,575,326
|
|
Lines of credit from related parties
|
|
|
12,615,579
|
|
|
|
11,914,092
|
|
Total liabilities
|
|
|
22,655,594
|
|
|
|
21,889,457
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Deficit
|
|
|
|
|
|
|
|
|
Preferred stock:
Authorized: 500,000,000
shares of preferred stock (December 31, 2020 - 500,000,000) with a par value of $0.001
per share Shares issued and outstanding: No Nil shares of preferred stock (December 31, 2020 - Nil) were issued and
outstanding
|
|
|
—
|
|
|
|
—
|
|
Common stock:
Authorized: 10,000,000,000 shares of common stock (December 31, 2020 - 10,000,000,000) with a par value of $0.001 per share Shares issued and outstanding: 542,716,344 shares of common stock (December 31, 2020 - 511,020,709)
|
|
|
542,716
|
|
|
|
511,020
|
|
Obligation to issue shares
|
|
|
—
|
|
|
|
200,000
|
|
Additional paid-in capital
|
|
|
74,145,100
|
|
|
|
71,100,134
|
|
Accumulated deficit
|
|
|
(96,909,215
|
)
|
|
|
(93,571,762
|
)
|
Stockholders’ deficit
|
|
|
(22,221,399
|
)
|
|
|
(21,760,608
|
)
|
Total liabilities and stockholders’ deficit
|
|
$
|
434,195
|
|
|
$
|
128,849
|
|
See accompanying notes
to the condensed consolidated financial statements.
ALR TECHNOLOGIES INC.
Condensed Consolidated Statements of Operations
($ United States)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three months ended
June 30,
|
|
Six months ended
June 30,
|
|
|
2021
|
|
2020
|
|
2021
|
|
2020
|
|
|
|
|
|
|
|
|
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product development costs
|
|
|
128,157
|
|
|
|
122,551
|
|
|
|
240,199
|
|
|
|
217,761
|
|
Professional fees
|
|
|
138,890
|
|
|
|
429,246
|
|
|
|
356,118
|
|
|
|
466,550
|
|
Selling, general and administrative
|
|
|
215,466
|
|
|
|
131,359
|
|
|
|
423,752
|
|
|
|
254,404
|
|
Operating Loss
|
|
|
482,513
|
|
|
|
683,156
|
|
|
|
1,020,069
|
|
|
|
938,715
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
1,804,403
|
|
|
|
525,636
|
|
|
|
2,283,770
|
|
|
|
1,044,627
|
|
Loss on settlement of debt
|
|
|
33,614
|
|
|
|
—
|
|
|
|
33,614
|
|
|
|
—
|
|
Total Other Items
|
|
|
1,838,017
|
|
|
|
525,636
|
|
|
|
2,317,384
|
|
|
|
1,044,627
|
|
Net Loss
|
|
$
|
(2,320,530
|
)
|
|
$
|
(1,208,792
|
)
|
|
$
|
(3,337,453
|
)
|
|
$
|
(1,983,342
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares of common stock outstanding, basic and diluted
|
|
|
532,676,344
|
|
|
|
270,777,909
|
|
|
|
527,072,440
|
|
|
|
270,291,721
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share, basic and diluted
|
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.01
|
)
|
See accompanying notes
to the condensed consolidated financial statements.
ALR TECHNOLOGIES INC.
Condensed Consolidated Statements of Cash
Flows
($ United States)
(Unaudited)
|
|
|
|
|
|
|
Six Months Ended
June 30,
|
|
|
2021
|
|
2020
|
|
|
|
|
|
OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(3,337,453
|
)
|
|
$
|
(1,983,342
|
)
|
Stock-based compensation-product development costs
|
|
|
97,842
|
|
|
|
18,804
|
|
Stock-based compensation-professional fees
|
|
|
43,295
|
|
|
|
391,843
|
|
Stock-based compensation-interest
|
|
|
1,287,834
|
|
|
|
—
|
|
Interest expense on lines of credit
|
|
|
670,452
|
|
|
|
719,455
|
|
Non-cash imputed interest expenses
|
|
|
60,059
|
|
|
|
60,737
|
|
Loss on settlement of debt
|
|
|
33,614
|
|
|
|
—
|
|
Changes in operating assets and liabilities
|
|
|
|
|
|
|
|
|
Decrease in prepaid expenses
|
|
|
5,103
|
|
|
|
—
|
|
Decrease in accounts payable and accrued liabilities
|
|
|
17,736
|
|
|
|
83,595
|
|
Increase in interest payable
|
|
|
264,100
|
|
|
|
265,834
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(857,418
|
)
|
|
|
(443,074
|
)
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
Proceeds from lines of credit
|
|
|
401,758
|
|
|
|
441,948
|
|
Repayment of lines of credit interest
|
|
|
(370,723
|
)
|
|
|
—
|
|
Proceeds from sales of shares of common stock
|
|
|
1,136,832
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
1,167,867
|
|
|
|
441,948
|
|
|
|
|
|
|
|
|
|
|
Change in cash
|
|
|
310,449
|
|
|
|
(1,126
|
)
|
Cash, beginning of period
|
|
|
66,190
|
|
|
|
1,838
|
|
Cash, end of period
|
|
$
|
376,639
|
|
|
$
|
712
|
|
See accompanying notes
to the condensed consolidated financial statements.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
1. Basis
of Presentation, Nature of Operations and Going Concern
ALR Technologies
Inc. (the “Company”) was incorporated under the laws of the state of Nevada on March 24, 1987. On May 16, 2020,
the Company incorporated a wholly owned subsidiary, ALR Technologies Sg Pte. Ltd. (“ALRT SG”), under the Companies Act
of Singapore. On June 9, 2021, the Company incorporated a wholly owned subsidiary, Canada Diabetes Solution Centre, Inc., under the
Business Corporations Act of Alberta. The Company has developed its Diabetes Management Solution, which is a comprehensive approach
to diabetes care consisting of data collection, predictive A1C, insulin dosage adjustment suggestions, performance tracking, remote monitoring
and diabetes test supplies. The Company is seeking commercial opportunities to deploy the Diabetes Management Solution in the United
States of America, Canada and Singapore.
These
unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles
in the United States of America (“U.S. GAAP”) in U.S. dollars and on a going concern basis, which presumes the realization
of assets and the discharge of liabilities and commitments in the normal course of operations for the foreseeable future. Several adverse
conditions cast substantial doubt on the validity of this assumption. The Company has incurred significant losses over the six-month
periods ended June 30, 2021 and 2020 of $3,337,453 and $1,983,342, respectively. As of June 30, 2021, the Company is unable
to self-finance its operations, has a working capital deficit of $22,221,399 (December 31, 2020 - $21,760,608), accumulated
deficit of $96,909,215 (December 31, 2020 - $93,571,762), limited resources, no source of operating cash flow and no assurance
that sufficient funding will be available to conduct continued product development activities. If the Company is able to finance its
required product development activities, there is no assurance the Company’s current projects will be commercially viable or profitable.
The Company has debts comprised of accounts payable and accrued liabilities, interest payable, lines of credit and promissory notes payable
totaling $22,655,594 currently due, due on demand or considered delinquent. There is no assurance that the Company will not face additional
legal action from creditors regarding delinquent accounts payable, promissory notes payable and interest payable. Any one or a combination
of these above conditions could result in the failure of the business and cause the Company to cease operations.
The Company’s
ability to continue as a going concern is dependent upon the continued financial support of its creditors and its ability to obtain financing
to fund working capital and overhead requirements, fund the development of the Company’s product line, and ultimately, the Company’s
ability to achieve profitable operations and repay overdue obligations. Management has obtained a mix of equity and line of credit financing
from related parties. The line of credit facilities have available borrowing in principal up to $12,300,000. As of June 30, 2021,
the total principal balance outstanding was $11,940,884. The resolution of whether the Company is able to continue as a going concern
is dependent upon the realization of management’s plans. There can be no assurance that the Company will be able to raise any additional
debt or equity capital from the sources described above or that the lenders in the line of credit arrangements will maintain the availability
of borrowing from the line. If management is unsuccessful in obtaining short-term financing or achieving long-term profitable operations,
the Company will be required to cease operations.
In March
2020, the World Health Organization declared coronavirus, COVID-19, a global pandemic. This contagious disease outbreak, which has continued
to spread, and any related adverse public health developments, has adversely affected workforces, economies and financial markets globally,
potentially leading to an economic downturn. Management does not expect that COVID-19 will have a significant impact on the Company;
however, it could have a potential impact on the Company’s ability to raise money, market its products to attract customers or
procure equipment and parts for its glucose monitoring system.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
1. Basis
of Presentation, Nature of Operations and Going Concern (continued)
All of
the Company’s debt is either due on demand or is in default, while continuing to accrue interest at its stated rate. The Company
will seek to obtain creditors’ consents to delay repayment of the outstanding promissory notes payable and related interest thereto,
until it is able to replace this financing with funds generated by operations, recapitalization with replacement debt or from equity
financings through private placements. While some of the Company’s creditors have agreed to extend repayment deadlines in the past,
there is no assurance that they will continue to do so in the future. In the past, creditors have successfully commenced legal action
against the Company to recover debts outstanding. In those instances, the Company was able to obtain financing from related parties to
cover the verdict or settlement; however, there is no assurance that the Company would be able to obtain the same financing in the future.
If the Company is unsuccessful in obtaining financing to cover any potential verdicts or settlements, the Company will be required to
cease operations.
The Company’s
activities will necessitate significant uses of working capital beyond 2021. Additionally, the Company’s capital requirements will
depend on many factors, including the success of the Company’s continued product development and distribution efforts. The Company
plans to continue financing its operations with the lines of credit it has available.
2. Significant
Accounting Policies
These
unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, ALR Technologies
Sg Pte. Ltd., which was incorporated on May 16, 2020 in Singapore, and Canada Diabetes Solution Centre, Inc., which was incorporated
on June 9, 2021 in Alberta. The Canadian subsidiary is currently inactive. All significant intercompany balances and transactions have
been eliminated on consolidation.
The unaudited
condensed consolidated financial statements as of June 30, 2021 and for the period then ended have been prepared pursuant to the
rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures normally included in annual
consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been
condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to
make the information not misleading.
In the
opinion of management, all adjustments necessary to present fairly the financial position as of June 30, 2021 and December 31, 2020
and the results of operations and cash flows as of June 30, 2021 and 2020, and for the periods then ended, have been made. Those
adjustments consist of normal and recurring adjustments.
These
unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes
thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
The results
of operations for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
3. Interest,
Advances and Promissory Notes Payable
a) Promissory
notes payable to related parties
A summary
of the promissory notes payable to related parties is as follows:
Schedule
of Promissory Notes Payable - Relatives of Board of Directors
|
|
|
|
|
Promissory Notes Payable to Related Parties
|
|
June 30,
2021
|
|
December 31, 2020
|
Promissory notes payable to relatives of directors collateralized by a general security agreement over all the assets of the Company, past maturity:
|
|
|
|
|
|
|
|
|
i. Interest at 1% per month
|
|
$
|
720,619
|
|
|
$
|
720,619
|
|
ii. Interest at 1.25% per month
|
|
|
51,347
|
|
|
|
51,347
|
|
iii. Interest at the U.S. bank prime rate plus 1%
|
|
|
100,000
|
|
|
|
100,000
|
|
iv. Interest at 0.5% per month
|
|
|
695,000
|
|
|
|
695,000
|
|
|
|
|
|
|
|
|
|
|
Promissory notes payable, unsecured, to relatives of a director, bearing interest at 1% per month, past maturity
|
|
|
1,465,000
|
|
|
|
1,465,000
|
|
Total Promissory Notes Payable to Related Parties
|
|
$
|
3,031,966
|
|
|
$
|
3,031,966
|
|
All amounts
past maturity continue to accrue interest at their stated rate and are considered due on demand.
b) Promissory
notes payable to unrelated parties
A summary
of the promissory notes payable to unrelated parties is as follows:
Schedule
of Activity of Promissory Notes Payable to Unrelated Lenders
|
|
|
|
|
Promissory Notes Payable to Unrelated Parties
|
|
June 30,
2021
|
|
December 31, 2020
|
Unsecured promissory notes payable to unrelated lenders, past maturity:
|
|
|
|
|
|
|
|
|
i. Interest at 1% per month
|
|
$
|
1,317,456
|
|
|
$
|
1,337,456
|
|
ii. Interest at 0.667% per month
|
|
|
425,000
|
|
|
|
435,985
|
|
iii. Interest at 0.625% per month
|
|
|
150,000
|
|
|
|
150,000
|
|
iv. Non-interest-bearing
|
|
|
270,912
|
|
|
|
270,912
|
|
|
|
|
|
|
|
|
|
|
Promissory notes payable, secured by a guarantee from the Chief Executive Officer, bearing interest at 1% per month, past maturity
|
|
|
60,000
|
|
|
|
60,000
|
|
Total Promissory Notes Payable to Unrelated Parties
|
|
$
|
2,223,368
|
|
|
$
|
2,254,353
|
|
During
the six months ended June 30, 2021, the Company:
|
·
|
extinguished
promissory notes totalling $20,000 through the issuance of shares of common stock (note 5).
|
|
·
|
Reallocated
amounts of $10,985 from promissory notes to interest payable
|
There was
no promissory note activity during the year-ended December 31, 2020.
All amounts
past maturity continue to accrue interest at their stated rate and are considered due on demand.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
3. Interest,
Advances and Promissory Notes Payable (continued)
c) Interest
payable
A
summary of the interest payable activity is as follows:
ScheduleofInterestPayable
|
|
|
|
|
Balance, December 31, 2019
|
|
$
|
5,364,997
|
|
Interest incurred on promissory notes payable
|
|
|
528,871
|
|
Interest payable retired through issuance of shares
|
|
|
(2,318,542
|
)
|
Balance, December 31, 2020
|
|
|
3,575,326
|
|
Reclassified from promissory notes payable
|
|
|
10,985
|
|
Interest incurred on promissory notes payable
|
|
|
264,100
|
|
Interest payable retired through issuance of shares
|
|
|
(3,000
|
)
|
Balance, June 30, 2021
|
|
$
|
3,847,411
|
|
Interest
payable is due to related and non-related parties as follows:
|
|
|
|
|
|
|
June 30,
2021
|
|
December 31, 2020
|
Related parties (relatives of the Chairman)
|
|
$
|
1,031,629
|
|
|
$
|
873,666
|
|
Non-related parties
|
|
|
2,815,782
|
|
|
|
2,701,660
|
|
|
|
$
|
3,847,411
|
|
|
$
|
3,575,326
|
|
The payment
terms, security and any interest payable are based on the underlying promissory notes payable that the Company has outstanding.
d) Interest
expense
During
the period ended June 30, 2021, the Company incurred interest expense of $2,283,770 (2020 - $1,044,627) as follows:
|
·
|
$1,287,834
(2020 - $nil) incurred related to the modification of options held by the Chairman and
his spouse that were granted in connection with financing provided to the Company;
|
|
·
|
$670,452
(2020 - $719,455) incurred on lines of credit payable as shown in note 4;
|
|
·
|
$264,100
(2020 - $264,435) incurred on promissory notes (notes 3(a) and 3(b));
|
|
·
|
$60,059
(2020 - $60,737) incurred from the calculation of imputed interest on accounts payable
outstanding for longer than one year, advances payable and promissory notes payable, which
had no stated interest rate; and
|
|
·
|
$1,325
(2020 - $nil) interest on other items.
|
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
4. Lines
of Credit
As of
June 30, 2021, the Company had two lines of credit as follows:
Schedule
Line of Credit Related Party
Creditor
|
Interest
Rate
|
Borrowing
Limit
|
Repayment
Terms
|
Principal
Borrowed
|
Accrued
Interest
|
Total
Outstanding
|
Security
|
Purpose
|
Chairman
and CEO
|
1%
per Month
|
$
10,300,000
|
Due
on Demand
|
$ 9,940,884
|
$
650,030
|
$
10,590,914
|
General
Security over Assets
|
General
Corporate Requirements
|
Wife
of Chairman
|
1%
per Month
|
2,000,000
|
Due
on Demand
|
2,000,000
|
24,665
|
2,024,665
|
General
Security over Assets
|
General
Corporate Requirements
|
Total
|
|
$
12,300,000
|
|
$
11,940,884
|
$
674,695
|
$
12,615,579
|
|
|
As of
December 31, 2020, the Company had two lines of credit as follows:
Creditor
|
Interest
Rate
|
Borrowing
Limit
|
Repayment
Terms
|
Principal
Borrowed
|
Accrued
Interest
|
Total
Outstanding
|
Security
|
Purpose
|
Chairman
and CEO
|
1%
per Month
|
$
10,300,000
|
Due
on Demand
|
$ 9,539,125
|
$
314,967
|
$ 9,854,092
|
General
Security over Assets
|
General
Corporate Requirements
|
Wife
of Chairman
|
1%
per Month
|
2,000,000
|
Due
on Demand
|
2,000,000
|
60,000
|
2,060,000
|
General
Security over Assets
|
General
Corporate Requirements
|
Total
|
|
$
12,300,000
|
|
$
11,539,125
|
$
374,967
|
$
11,914,092
|
|
|
On September 21,
2020, the Company, the Chairman and the Chairman’s spouse agreed to retire a portion of the principal of $1,038,967 and accrued
interest of $8,642,491 pursuant to two shares for debt agreements (note 5(b)).
5. Capital
Stock
|
a)
|
Authorized
capital stock
|
10,000,000,000
shares of common stock with a par value of $0.001 per share.
500,000,000
shares of preferred stock with a par value of $0.001 per share.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
5. Capital
Stock (continued)
b) Issued
capital stock
During
the period ended June 30, 2021:
|
i)
|
On
January 4, 2021, 1,000 shares of common stock were cancelled by a shareholder; no consideration
was exchanged.
|
|
ii)
|
On
April 12, 2021, the Company elected to extend the initial 90-day period (April 22, 2021)
by an additional 100-day period related to the closing of the Rights Offering. The Company
had until July 31, 2021 to sell the remaining 113,025,592 shares of common stock. Subsequent
to June 30, 2021 the Company extended the offering period to October 29, 2021 (note 10(b)).
|
|
iii)
|
The
Company collected subscriptions of $1,124,832 pursuant to its registration statement and
issued a total of 26,496,635 shares of common stock for gross proceeds of $1,324,832; $200,000
of the proceeds had been collected during the year ended December 31, 2020 and recognized
as obligation to issue shares.
|
|
iv)
|
The
Company received proceeds of $12,000 pursuant to the exercise of options to acquire 800,000
shares of common stock at a price of $0.015 per share.
|
|
v)
|
The
Company entered into two shares for debt agreements with two creditors to issue an aggregate
4,400,000 shares of common stock at fair value of $0.057 per share for a purchase price of
$250,800 in exchange for the retirement of $217,186 of liabilities comprised of:
|
|
·
|
Accounts
payable - $ 194,186
|
|
·
|
Promissory
notes – Principal - $ 20,000
|
|
·
|
Line
of credit – Accrued interest - $ 3,000
|
The Company
recognized loss on debt settlement of $33,614. The Company also issued commitment letters to two creditors offering them an aggregate
20,000,000 shares of common stock in exchange for the extinguishment of $1,511,377 in promissory notes and interest payable prior to
December 31, 2021.
During
the year ended December 31, 2020:
|
i)
|
On
February 11, 2020, the Company issued 2,000,000 restricted shares of common stock at a price
of $0.04 per share with a value of $80,000 in exchange for the retirement of $60,000 of accounts
payable and $20,000 for the provision of services.
|
|
ii)
|
On
August 24, 2020, the Company issued 242,800 restricted shares of common stock at a price
of $0.05 per share for proceeds of $12,140.
|
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
5. Capital
Stock (continued)
b) Issued
capital stock (continued)
During
the year ended December 31, 2020: (continued)
|
iii)
|
On
September 21, 2020, the Company entered into two shares for debt agreements with the Chairman
and his spouse to issue an aggregate 240,000,000 restricted shares of common stock at a price
of $0.05 per share for a purchase price of $12,000,000 in exchange for the retirement of
$12,000,000 of liabilities comprised of:
|
|
·
|
Promissory
notes – Accrued interest - $ 2,318,542
|
|
·
|
Line
of credit – Accrued interest - $ 8,642,491
|
|
·
|
Line
of credit – Principal - $ 1,038,967
|
|
iv)
|
On
December 4, 2020, the Company filed a Form S-1 Registration Statement to distribute subscription
rights to purchase up to an aggregate 127,522,227 shares of common stock at a price of $0.05
per share for maximum aggregate offering proceeds of $6,376,111. The Company collected subscriptions
of $200,000 related to management’s right to allocate unsubscribed shares of common
stock.
|
6. Additional
Paid-in Capital
Stock
options
A summary
of stock option activity is as follows:
Schedule
of Share-based Compensation, Stock Options, Activity
|
Six
Months Ended
June 30,
2021
|
Year
Ended
December 31,
2020
|
|
Number
of Options
|
Weighted
Average Exercise Price
|
Number
of Options
|
Weighted
Average Exercise Price
|
Outstanding,
beginning of period
|
5,362,701,500
|
$
|
0.004
|
5,236,401,500
|
$
|
0.003
|
Granted
|
92,500,000
|
$
|
0.050
|
139,800,000
|
$
|
0.047
|
Exercised
|
(800,000)
|
$
|
(0.015)
|
-
|
$
|
-
|
Cancelled
|
(7,400,000)
|
$
|
(0.033)
|
(13,500,000)
|
$
|
(0.034)
|
Outstanding,
end of period
|
5,447,001,500
|
$
|
0.005
|
5,362,701,500
|
$
|
0.004
|
|
|
|
|
|
|
|
Exercisable,
end of period
|
5,194,501,500
|
$
|
0.003
|
5,202,701,500
|
$
|
0.003
|
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
6. Additional
Paid-in Capital (continued)
Stock
options (continued)
During
the period ended June 30, 2021:
On January
28, 2021, the Company granted the option to acquire an aggregate 32,000,000 shares of common stock at a price of $0.05 per share to six
individuals. All of the options will vest according to performance or time-based conditions. Options to acquire 22,000,000 shares of
common stock will expire December 31, 2025, and options to acquire 10,000,000 shares of common stock will expire May 17, 2024.
None of these options have vested to date. The fair value of the options granted totals $1,706,244, of which $573,292 relates to stock
options that have time-based vesting conditions and $1,132,952 relates to stock options that have performance vesting conditions. During
the current period, $112,813 relates to the stock options with time-based vesting conditions, which was recorded. The remaining fair
value of $1,593,431 has not been recorded.
On February
22, 2021, the Company granted the option to acquire an aggregate 5,000,000 shares of common stock at a price of $0.05 per share. These
options were granted to three individuals and have an expiry date of May 17, 2024. None of these options have vested to date. The fair
value of the options granted totals $225,141. During the current period, $23,092 relates to stock options with time-based vesting conditions,
which was recorded. The remaining fair value of $202,049 has not been recorded.
On April
14, 2021, the Company’s Board of Directors approved the grant of the option to acquire an aggregate 28,500,000 shares of common
stock at a price of $0.05 per share until December 31, 2025 to five individuals. All of the options will vest according to performance
or time-based conditions. None of these options have vested to date. The fair value of the options granted totals $1,565,812, of which
$351,621 relates to stock options that have time-based vesting conditions and $1,214,191 relates to stock options that have performance
vesting conditions. During the current period, $5,232 relates to the stock options with time-based vesting conditions, which was recorded.
The remaining fair value of $1,560,580 has not been recorded.
On May
12, 2021, the Company’s Board of Directors amended the option to acquire 2,000,000 shares, previously granted on January 28, 2021
to a consultant, to increase the option by 1,000,000 to provide the optionee the option to acquire an aggregate of 3,000,000 shares of
common stock at a price of $0.05 per share until December 31, 2025. All other terms of the January 28, 2021 grant remain the same
and the options are subject to performance vesting conditions. The fair value of the additional 1,000,000 amended options granted totaling
$54,940 was not recorded, as it cannot be determined that it is more likely than not that the performance
condition will be met.
On May
31, 2021, the Company granted one consultant the option to acquire 5,000,000 shares of common stock of the Company at a price of $0.05
per share until December 31, 2025 subject to performance vesting conditions. The fair value of the options granted totaling $254,708
was not recorded, as it cannot be determined that it is more likely than not that the performance
condition will be met.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
6. Additional
Paid-in Capital (continued)
Stock
options (continued)
During
the period ended June 30, 2021: (continued)
On June
27, 2021, the Company cancelled 7,400,000 stock options with an average exercise price of $0.033.
On June
27, 2021, the Company’s Board of Directors approved the grant of the option to acquire an aggregate 21,000,000 shares of common
stock at a price of $0.05 per share until June 30, 2026 to four individuals. All of the options will vest according to performance
or time-based conditions. None of these options have vested to date. The fair value of the options granted totals $1,374,208, of which
$26,175 relates to stock options that have time-based vesting conditions and $1,348,033 relates to stock options that have performance
vesting conditions. The fair value of $1,374,208 has not been recorded.
On June
30, 2021, the Company amended the option to acquire 4,365,001,300 shares of common stock granted on July 1, 2016 by extending the
expiry date from July 1, 2021 to April 12, 2024. The options were granted in connection with lines of credit provided by the
Chairman and his spouse which are currently outstanding (note 4). All of the options had vested in previous years. The fair value of
the amendments totaled $1,287,834 and was recorded during the current period in interest expense.
During
the year ended December 31, 2020:
On April
1, 2020, the Company granted one consultant the option to acquire 10,000,000 shares of common stock at a price of $0.035 per share for
a term of five years. The fair value of the options granted totaling $391,843 was fully recorded at grant.
On May
12, 2020, the Company amended the option to acquire 40,000,000 shares of common stock granted on June 12, 2019 to extend the period
of vesting from May 31, 2020 to December 31, 2020. None of these options have vested to date.
On May
18, 2020, the Company granted one consultant the option to acquire 500,000 shares of common stock of the Company at a price of $0.035
per share until May 17, 2024. The fair value of the options granted totaling $18,725 was fully recorded at grant.
On June
1, 2020, the Company granted one consultant the option to acquire 10,000,000 shares of common stock of the Company at a price of $0.035
per share until May 31, 2025 subject to performance vesting conditions. The fair value of the options granted totaling $621,853
was not recorded, as it cannot be determined that it is more likely than not that the performance
condition will be met.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
6. Additional
Paid-in Capital (continued)
Stock
options (continued)
During
the year ended December 31, 2020: (continued)
On June
5, 2020, the Company granted one sales agent the option to acquire 10,000,000 shares of common stock of the Company at a price of $0.035
per share until May 31, 2025 subject to the agent enrolling 20,000 patients into the ALRT Diabetes Solution by May 31, 2021.
The fair value of the options granted totaling $494,868 was not recorded, as it cannot be determined
that it is more likely than not that the performance condition will be met.
On September
1, 2020, the Company granted thirteen individuals the option to acquire an aggregate 74,500,000 options at an exercise price of $0.05
per share; 22,000,000 stock options, which vested at the time of grant, will expire on May 17, 2024 and 52,500,000 stock options,
which vest upon achievement of performance conditions, will expire on May 31, 2025. None of the stock options with performance vesting
conditions have vested. The fair value of the options granted totals $3,854,619, of which $1,137,397
related to the stock options that have vested was recorded and $2,717,222 related to the options that have not vested was not recorded.
On October
12, 2020, the Company granted eight individuals the option to acquire an aggregate 34,800,000 options at an exercise price of $0.05 per
share until May 31, 2025; 18,300,000 vested at the time of grant and 16,500,000 of the stock options granted will vest upon achievement
of performance conditions. None of the stock options with performance vesting conditions have vested. The fair value of the options granted
totals $2,434,053, of which $1,279,973 related to the stock options that have vested was recorded
and $1,154,080 related to the options that have not vested was not recorded.
During
the year ended December 31, 2020, the Company recorded a further $79 in compensation expense related to the vesting of stock options
granted in previous years.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
6. Additional
Paid-in Capital (continued)
Stock
options (continued)
Outstanding:
The
options outstanding at June 30, 2021 and December 31, 2020 were as follows:
Schedule
of Options Outstanding
|
June 30,
2021
|
December 31,
2020
|
Expiry
Date
|
Options
|
Exercise
Price
|
Intrinsic
Value
|
Options
|
Exercise
Price
|
Intrinsic
Value
|
|
|
|
|
|
|
|
|
|
|
|
July
1, 2021
|
-
|
$
|
0.002
|
$
|
0.058
|
4,365,001,300
|
$
|
0.002
|
$
|
0.069
|
July
22, 2021
|
22,500,000
|
$
|
0.035
|
$
|
0.025
|
-
|
$
|
-
|
$
|
-
|
November
27, 2022
|
5,600,000
|
$
|
0.015
|
$
|
0.045
|
6,950,000
|
$
|
0.015
|
$
|
0.056
|
January
31, 2023
|
40,500,000
|
$
|
0.015
|
$
|
0.045
|
40,500,000
|
$
|
0.015
|
$
|
0.056
|
June
13, 2023
|
5,000,000
|
$
|
0.015
|
$
|
0.045
|
5,000,000
|
$
|
0.015
|
$
|
0.056
|
October
1, 2023
|
-
|
$
|
0.050
|
$
|
0.010
|
300,000
|
$
|
0.050
|
$
|
0.021
|
February
3, 2024
|
-
|
$
|
0.035
|
$
|
0.025
|
10,000,000
|
$
|
0.035
|
$
|
0.036
|
March
14, 2024
|
6,650,000
|
$
|
0.035
|
$
|
0.025
|
9,150,000
|
$
|
0.035
|
$
|
0.036
|
April
12, 2024
|
4,925,001,500
|
$
|
0.002
|
$
|
0.058
|
560,000,200
|
$
|
0.002
|
$
|
0.069
|
April
12, 2024
|
3,350,000
|
$
|
0.015
|
$
|
0.045
|
3,900,000
|
$
|
0.015
|
$
|
0.056
|
April
12, 2024
|
200,000
|
$
|
0.030
|
$
|
0.030
|
200,000
|
$
|
0.030
|
$
|
0.041
|
May
6, 2024
|
13,000,000
|
$
|
0.035
|
$
|
0.025
|
13,000,000
|
$
|
0.035
|
$
|
0.036
|
May
17, 2024
|
77,000,000
|
$
|
0.050
|
$
|
0.010
|
62,000,000
|
$
|
0.050
|
$
|
0.021
|
May
17, 2024
|
19,400,000
|
$
|
0.035
|
$
|
0.025
|
25,400,000
|
$
|
0.035
|
$
|
0.036
|
June
17, 2024
|
5,000,000
|
$
|
0.050
|
$
|
0.010
|
5,000,000
|
$
|
0.050
|
$
|
0.021
|
June
17, 2024
|
-
|
$
|
0.035
|
$
|
0.025
|
5,000,000
|
$
|
0.035
|
$
|
0.036
|
August
16, 2024
|
2,500,000
|
$
|
0.050
|
$
|
0.010
|
2,500,000
|
$
|
0.050
|
$
|
0.021
|
September
6, 2024
|
1,000,000
|
$
|
0.050
|
$
|
0.010
|
1,000,000
|
$
|
0.050
|
$
|
0.021
|
September
17, 2024
|
-
|
$
|
0.035
|
$
|
0.025
|
5,000,000
|
$
|
0.035
|
$
|
0.036
|
October
3, 2024
|
3,500,000
|
$
|
0.035
|
$
|
0.025
|
3,500,000
|
$
|
0.035
|
$
|
0.036
|
October
24, 2024
|
2,000,000
|
$
|
0.035
|
$
|
0.025
|
2,000,000
|
$
|
0.035
|
$
|
0.036
|
December
11, 2024
|
120,000,000
|
$
|
0.015
|
$
|
0.045
|
120,000,000
|
$
|
0.015
|
$
|
0.056
|
April
1, 2025
|
10,000,000
|
$
|
0.035
|
$
|
0.025
|
10,000,000
|
$
|
0.035
|
$
|
0.036
|
May
31, 2025
|
20,000,000
|
$
|
0.035
|
$
|
0.025
|
20,000,000
|
$
|
0.035
|
$
|
0.036
|
May
31, 2025
|
87,300,000
|
$
|
0.050
|
$
|
0.010
|
87,300,000
|
$
|
0.050
|
$
|
0.021
|
December
31, 2025
|
56,500,000
|
$
|
0.050
|
$
|
0.010
|
-
|
$
|
-
|
$
|
-
|
June 30,
2026
|
21,000,000
|
$
|
0.050
|
$
|
0.010
|
-
|
$
|
-
|
$
|
-
|
Total
|
5,447,001,500
|
$
|
0.005
|
$
|
0.055
|
5,362,701,500
|
$
|
0.004
|
$
|
0.066
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
Average Remaining Contractual Life
|
|
|
2.83
|
|
|
|
|
1.05
|
|
|
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
6. Additional
Paid-in Capital (continued)
Stock
options (continued)
The
fair value of the stock options granted and vested was allocated as follows:
Schedule
of Fair Value of Stock Options Granted-Allocation
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, 2021
|
|
Three Months Ended
June 30, 2020
|
|
Six Months Ended
June 30, 2021
|
|
Six Months Ended
June 30, 2020
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
$
|
1,287,834
|
|
|
$
|
—
|
|
|
$
|
1,287,834
|
|
|
$
|
—
|
|
Product development expense
|
|
|
61,697
|
|
|
|
18,725
|
|
|
|
97,842
|
|
|
|
18,804
|
|
Professional expense
|
|
|
28,070
|
|
|
|
391,843
|
|
|
|
43,295
|
|
|
|
391,843
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,377,601
|
|
|
$
|
410,568
|
|
|
$
|
1,428,971
|
|
|
$
|
410,647
|
|
The
Company uses the fair value method for determining stock-based compensation for all options granted during the fiscal periods. The fair
value was determined using the Black-Scholes option pricing model based on the following weighted average assumptions:
Schedule
of Share-based Payment Award, Stock Options, Valuation Assumptions
|
|
|
|
|
|
|
June 30,
2021
|
|
December 31, 2020
|
Risk-free interest rate
|
|
|
0.66
|
%
|
|
|
0.20
|
%
|
Expected life
|
|
|
4.6 years
|
|
|
|
4.6 years
|
|
Expected dividends
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected volatility
|
|
|
271
|
%
|
|
|
312
|
%
|
Forfeiture rate
|
|
|
0
|
%
|
|
|
0
|
%
|
The
weighted average fair value for the options granted during the six months ended June 30, 2021 was $0.06 (year ended December 31,
2020 - $0.06).
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
7. Related
Party Transactions and Balances
Schedule of related party transactions
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, 2021
|
|
Three Months Ended
June 30, 2020
|
|
Six Months Ended
June 30, 2021
|
|
Six Months Ended
June 30, 2020
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
Related party transactions included within interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expenses on promissory notes issued to relatives of the Chairman & Chief Executive Officer of the Company
|
|
|
78,981
|
|
|
|
79,171
|
|
|
|
157,963
|
|
|
|
157,963
|
|
Interest expense on lines of credit payable to the Chairman & Chief Executive Officer of the Company and his spouse
|
|
|
355,715
|
|
|
|
363,001
|
|
|
|
670,452
|
|
|
|
719,455
|
|
Interest expense related to the modification of stock options held by the Chairman and Chief Executive Officer of the Company and his spouse related to financing provided
|
|
|
1,287,834
|
|
|
|
—
|
|
|
|
1,287,834
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related party transactions including within selling, general and administration expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consulting fees to the Chairman & Chief Executive Officer of the Company accrued on the line of credit available to the Company
|
|
|
62,400
|
|
|
|
62,400
|
|
|
|
124,800
|
|
|
|
124,800
|
|
Salary to the spouse of the Chairman & Chief Executive Officer of the Company for services as VP Corporate and Director of the Singapore subsidiary
|
|
|
11,254
|
|
|
|
—
|
|
|
|
11,254
|
|
|
|
—
|
|
Loss on settlement of debt to a relative of the Chairman & Chief Executive Officer of the Company
|
|
|
16,800
|
|
|
|
—
|
|
|
|
16,800
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related party transaction included within product development expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consulting fees to a relative of the Chairman and Chief Executive Officer of the Company
|
|
|
—
|
|
|
|
30,000
|
|
|
|
—
|
|
|
|
60,000
|
|
Interest
on promissory notes payable to related parties, management compensation and compensation paid to a relative of a director have been recorded
at the exchange amount, which is the amount agreed to by the parties. Options granted to related parties have been recorded at their
estimated fair value.
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
8. Commitments
and Contingencies
The Company
has had three judgments against it relating to overdue promissory notes and accrued interest, and a fourth creditor has demanded repayment
of an overdue promissory note and accrued interest. To date, the Company has not repaid any of these promissory notes and related accrued
interest and could be subject to further action. The legal liability, totaling $1,234,382, of these promissory notes and related accrued
interest have been fully recognized and recorded by the Company. The Company has accrued interest of $267,457 related to one of these
promissory notes.
On December
22, 2020 a default judgement was entered against the Company in regards to one of the above noted judgments totaling $551,576, consisting
of the principal amount of $300,000 and accrued interest of $251,576, as of the date of the Civil Summons.
The Company
has a consulting arrangement with Mr. Sidney Chan, Chief Executive Officer and Chairman of the Board of Directors of the Company. Under
the terms of the contract, Mr. Chan will be paid $240,000 per annum for services as Chief Executive Officer. The contract can be terminated
at any time with thirty days’ notice and the payment of two years’ annual salary. Should the contract be terminated, all
debts owed to Mr. Chan and his spouse must be immediately repaid. The initial term of the contract is for one year and automatically
renews for continuous one-year terms. Also, under the terms of the contract are the following:
|
i.
|
Incentive
revenue bonus
|
Mr. Chan
will be entitled to a 1% net sales commission from the sales of any of the Company’s products at any time during his life, regardless
if Mr. Chan is still under contract with the Company.
If more
than 50% of the Company’s stock or assets are sold, Mr. Chan will be compensated for entering into non-compete agreements based
on the selling price of the Company or its assets as follows:
|
·
|
2%
of sales price up to $24,999,999 plus
|
|
·
|
3%
of sales price between $25,000,000 and $49,999,999 plus
|
|
·
|
4%
of sales price between $50,000,000 and $199,999,999 plus
|
|
·
|
5%
of sales price in excess of $200,000,000.
|
ALR TECHNOLOGIES INC.
Notes to Condensed Consolidated Financial
Statements
For the Six Months Ended June 30,
2021
($ United States)
(Unaudited)
9. Operating
Segments
The Company
has one operating segment, development of diabetes hardware and software. The Company’s geographical segments are summarized as
follows:
Schedule
of Operating Segments
|
|
|
|
|
|
|
June
30,
2021
|
|
December 31, 2020
|
Current and Total Assets
|
|
|
|
|
|
|
|
|
Other
|
|
$
|
14,963
|
|
|
$
|
7,632
|
|
Singapore
|
|
|
307,167
|
|
|
|
20,000
|
|
United States
|
|
|
112,065
|
|
|
|
101,217
|
|
|
|
$
|
434,195
|
|
|
$
|
128,849
|
|
|
|
|
|
|
|
|
Six Months Ended
June 30, 2021
|
|
Six Months Ended
June 30, 2020
|
Net Loss
|
|
|
|
|
|
|
|
|
Singapore
|
|
$
|
(77,666
|
)
|
|
$
|
—
|
|
United States
|
|
|
(3,259,787
|
)
|
|
|
(1,983,342
|
)
|
|
|
$
|
(3,337,453
|
)
|
|
$
|
(1,983,342
|
)
|
10. Subsequent
Events
|
a)
|
Effective
July 22, 2021, the Company cancelled 22,500,000 stock options exercisable at $0.035 related
to the termination of certain contractors and advisors.
|
|
b)
|
Effective
July 19, 2021, the Company extended the outside offering date to place the remaining 101,025,592
rights to purchase shares of common stock from July 31, 2021 to October 29, 2021.
|
|
ITEM
2.
|
MANAGEMENT
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
|
Forward-Looking Statements
The
following information must be read in conjunction with the unaudited Condensed Consolidated Financial Statements and Notes thereto included
in Item 1 of this Quarterly Report and the audited Consolidated Financial Statements and Notes thereto and Management’s Discussion
and Analysis or Plan of Operations contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Except
for the description of historical facts contained herein, the Form 10-Q contains certain forward-looking statements concerning future
applications of the Company’s technologies and the Company’s proposed services and future prospects, that involve risk and
uncertainties, including the possibility that the Company will: (i) be unable to commercialize services based on its technology, (ii)
ever achieve profitable operations, or (iii) not receive additional financing as required to support future operations, as detailed herein
and from time to time in the Company’s future filings with the Securities and Exchange Commission (“SEC”) and elsewhere.
Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in the forward-looking statements.
Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we
do not intend to update any of the forward-looking statements to conform these statements to actual results.
Our
consolidated financial statements are stated in United States dollars and are prepared in accordance with United States generally accepted
accounting principles.
In
this quarterly report, unless otherwise specified, all references to “common shares” refer to the common shares in our capital
stock.
As
used in this quarterly report, the terms “we”, “us”, “our”, the “Company” and “ALRT”
mean ALR Technologies Inc., unless otherwise indicated.
Overview
ALR
TECHNOLOGIES, INC. was incorporated under the laws of the state of Nevada on March 24, 1987 as Mo Betta Corp. In April 1998, the
Company changed its business purpose to marketing a pharmaceutical compliance device.
In
December 1998, the common shares of the Company began trading on the Bulletin Board operated by the National Association of Securities
Dealers Inc. under the symbol “MBET.” On December 28, 1998, the Company changed its name from Mo Betta Corp. to ALR
Technologies Inc. Subsequently, the symbol was changed to “ALRT”.
During
2011, the Company received Food and Drug Administration (“FDA”) clearance and achieved Health Insurance Portability and
Accountability Act of 1996 (HIPAA) compliance for its earlier version of the Diabetes Solution. With these key achievements and successful
clinical trials completed, the Company undertook a pilot program in 2014. The Company obtained significant findings from this pilot program,
which led to the development of its Insulin Dosage Adjustment (“IDA”).
During
2017, the Company received FDA clearance for Insulin Dose Adjustment (“IDA”) and submitted worldwide patent application under
the patent cooperation treaty to the World Intellectual Property Organization for the Predictive A1C innovation it has licensed from
its Chief Executive Officer. The Company is actively seeking to commence
revenue-generating activities for its Diabetes Solution in Singapore and is conducting further pilot programs in the United States and
Singapore.
Recent Developments
On
January 28, 2021, the Company’s Board of Directors approved the grant of options to six individuals to acquire an aggregate 32,000,000
shares of common stock at an exercise price of $0.05 per share with expiry dates between May 17, 2024 and December 31, 2025.
All of the options granted have vesting conditions, of which 12,000,000 are time-based vesting conditions and 20,000,000 are performance-based
vesting conditions.
On
February 22, 2021, the Company granted three individuals the option to acquire an aggregate 5,000,000 shares of common stock at an exercise
price of $0.05 per share until May 17, 2024. All of the options granted will not vest until immediately before expiry.
On
April 14, 2021, the Company’s Board of Directors approved the grant of options to acquire an aggregate 28,500,000 shares of common
stock at a price of $0.05 per share until December 31, 2025. The options to acquire shares will vest according to performance or
time-based conditions and none of these options granted had vested as of the date of this report.
The
Company entered into two Debt Settlement Agreements whereby the Company has agreed to issue an aggregate 4,400,000 shares of common stock
to two creditors of the Company to extinguish $194,186 in accounts payable and $23,000 in promissory notes and interest. The shares were
issued on May 10, 2021. The Company also issued commitment letters to two creditors offering them an aggregate of 20,000,000 shares of
common stock in exchange for the extinguishment of $1,511,377 in promissory notes and interest payable prior to December 31, 2021.
On
May 12, 2021, the Company’s Board of Directors amended the option to acquire 2,000,000 shares, previously granted on January 28,
2021 to a consultant, to 3,000,000 shares of common stock at a price of $0.05 per share until December 31, 2025. All other terms
of the January 28, 2021 grant remain the same and the options are subject to performance vesting conditions.
On
May 31, 2021, the Company granted one consultant the option to acquire 5,000,000 shares of common stock of the Company at a price of
$0.05 per share until December 31, 2025 subject to performance vesting conditions.
On
June 1, 2021, the Company announced that it is taking steps to redomicile the Company to Singapore. As part of the process, the Company
intends to effect a share exchange plan of merger under the laws of Nevada and Singapore in which shareholders will exchange their shares
of the Company for shares in a Singapore entity, on a one-for-one basis, with the Singapore entity becoming the parent company. The transaction
will be subject to shareholder approval and approval of the relevant corporate and securities regulatory authorities in both jurisdictions
where required.
On
June 8, 2021, the Company announced the establishment of the ALRT Animal Health Division, a new business division, which will introduce
the world’s first and only Continuing Glucose Monitoring System (“CGMS”) for diabetic companion animals.
On
June 22, 2021, the Company provided termination notices to four individuals which included that they would have 30 days to exercise their
options, or those options would be cancelled. As a result a total of 22,500,000 stock options granted in 2019 with an exercise price
of $0.035 expired unexercised on July 22, 2021.
On
June 27, 2021, the Company’s Board of Directors cancelled 7,400,000 stock options granted in previous years to three individuals
with an average exercise price of $0.033. These individuals have not provided services to the Company since mid-2020. All of the options
had vested in previous years.
On
June 27, 2021, the Company’s Board of Directors approved the grant of the option to acquire an aggregate 21,000,000 shares of common
stock at a price of $0.05 per share until June 30, 2026 to four individuals. All of the options will vest according to performance
or time-based conditions. None of these options have vested to date.
On
June 30, 2021, the Company amended the option to acquire 4,365,001,300 shares of common stock granted on July 1, 2016 by extending
the expiry date from July 1, 2021 to April 12, 2024. All of the options had vested in previous years.
Recent Developments
– Subsequent to June 30, 2021
Effective
July 22, 2021, the Company cancelled 22,500,000 stock options exercisable at $0.035 related to the termination of certain contractors
and advisors.
On
July 19, 2021, the Company elected to extend the outside date to place the remaining rights under the rights offering from July 31, 2021
to October 29, 2021 (see below under Financing).
Financing
Rights
Offering
On
December 4, 2020, the Company filed a Form S-1 Registration Statement to distribute subscription rights to purchase up to an aggregate
127,522,227 shares of our common stock at a price of $0.05 per share. As at June 30, 2021, the Company issued 26,496,635 unrestricted
shares of common stock related to proceeds received of $1,324,832. The Company has until October 29, 2021 to sell the remaining 101,025,592
shares of common stock for total proceeds of $5,051,280, if exercised.
Exercise
of Stock Options
On
February 8, 2021, the Company issued 800,000 shares of common stock for proceeds of $12,000 for the exercise of options at $0.015 per
share.
Products
ALRT
has developed its Diabetes Solution product by utilizing internet-based technologies to facilitate the healthcare provider’s (“HCPs”)
ability to monitor their diabetes patients’ health and ensure adherence to health maintenance activities.
The
ALRT Diabetes Solution is a remote monitoring and care facilitation platform that allows patients to upload the blood glucose data from
their blood glucose meters on a weekly basis. The ALRT System processes and converts each data set to a predictive A1C value and shares
it with the patient’s physician. The System provides the physician with therapy advancement suggestions based on current clinical
practice guidelines. Patients receive therapy assessments and adjustments in much shorter cycles, keeping A1Cs at target, mitigating
diabetes complications and lowering costs of care.
ALRT
previously conducted a clinical trial utilizing manual blood glucose data analysis and follow-up care. The trial demonstrated that remote
diabetes care is associated with significant lowering of A1C levels. The study concluded that continuing intervention using an internet-based
glucose monitoring system is an effective way of improving glucose control compared to conventional care. A second clinical trial demonstrated
that this type of Internet-based Blood Glucose Monitoring System (“IBGMS”) was associated with comparable reductions in A1C
levels with that of more expensive CGMS. The Company is planning further trials to demonstrate the added value of the predictive A1C
and therapy advancement features of the ALRT System.
In
the future, the Company may seek to adapt its Diabetes Solution to be used in the management of other chronic diseases. The Company may
be required to obtain additional clearance from the FDA prior to commencing selling activities in the United States for other chronic
health conditions.
Diabetes
is a leading cause of death, serious illness and disability across North America. By the year 2030, it is expected that 1 in 10 adults,
globally, will have diabetes (diagnosed and undiagnosed instances). We believe diabetes is a global pandemic.
Data
from the American Diabetes Association (“ADA”) shows 30 million Americans have diabetes and 84 million have prediabetes.
That is 1 in 3 Americans coping with the disease or serious threat of it. The total cost of diagnosed diabetes is staggering at $327 billion
annually ($237 billion in direct medical costs and $90 billion in reduced productivity), putting serious drag on an already
strained healthcare system. Taking a broader view, the global cost of diabetes was estimated at a whopping $825 billion annually
in 2016.
Diabetes
is a lifelong chronic disease with no cure. However, people with diabetes can take steps to control their disease and reduce the risk
of developing the associated serious complications, thereby controlling healthcare costs. The Canadian Diabetes Association Clinical
Practice Guidelines Expert Committee reports that, “Successful diabetes care depends on the daily commitment of persons with diabetes
mellitus to self-manage through the balance of lifestyle and medication. Diabetes care should be organized around a multi- and interdisciplinary
diabetes healthcare team that can establish and sustain a communication network between the person with diabetes and the necessary healthcare
and community systems”. Diabetes incidence rates, economic costs and human costs are increasing even though we know how to control
the disease. The Diabetes Control and Complication Trial conducted from 1983 to 1993 outlined management as follows:
|
·
|
Testing
blood glucose levels four or more times per day;
|
|
·
|
Injecting
insulin at least three times a day or using an insulin pump;
|
|
·
|
Adjusting
insulin dose according to food intake and exercise;
|
|
·
|
Following
a diet and exercise plan; and
|
|
·
|
Monthly
visits to healthcare team.
|
We
believe there are five causes why diabetes is not controlled:
|
1.
|
Patient
non-adherence;
|
|
5.
|
Insulin
under-prescription.
|
Patient Non-adherence
As
noted in Patrick Connole, “UnitedHealthcare, Other Large Insurers Seek Better Adherence to Diabetes Care”, Health Plan
Week, February 11, 2013, Volume 23, Issue 5, 80% of United States patients with diabetes do not follow their prescribed care plan.
Central to conventional diabetes care is patient self-management.
Unreliable Data
As
noted in Gonder-Frederick, L.A., et al, “Self Measurement of Blood Glucose: Accuracy of Self-Reporting Data and Adherence to
Recommended Regimen” Diabetes Care, Volume 11, no. 7, July 1988, 77% of patient data contain errors.
Data Overload
HCPs
face a lack of timely and reliable blood glucose data, resulting in delays to advance therapy and sub-optimal insulin dosing. The amount
of patient data for clinicians to analyze is too vast and significant during 15-minute clinical appointments, and the information
they have is unreliable.
Clinical Inertia
As
noted in Khunti, K., et al, “Clinical Inertia in People with Type 2 Diabetes: A Retrospective Cohort Study of More than 80,000
People.” Diabetes Care, Volume 36, no. 11, July 2013, across over 80,000 patients, when A1C goals were not met, therapy intensification
was late across every measure. It took on average 19 months to escalate patients with an average A1C of 8.7% from single medication to
dual therapy and 82 months to escalate patients with an average A1C of 8.8% from dual medication to triple therapy. Furthermore, they
found that it took approximately 20 years to advance patients with an average A1C of over 9% to insulin. At the end of the study, less
than 50% of the patients had their treatment intensified.
Furthermore,
in Treatment intensification for patients with type 2 diabetes and poor glycaemic control by Fu and Sheenan, it was noted that
out of 11,525 patients investigated with an A1C greater than 8% patients received intensification as follows:
|
·
|
11%
within 6-12 months; and
|
Failure
to respond to higher than targeted A1C with treatment intensification puts patients with escalated A1C at risk for complications and
diabetes-associated co-morbidities.
Insulin Under-prescription
Insulin
dosing is complex requiring review of large amounts of data, which takes significant amounts of time. We believe HCPs routinely under-prescribe
insulin to ensure they avoid insulin dosage adjustments, which could result in hypoglycemia for their patients.
Cleveland Clinic
Study
A
team at Cleveland Clinic examined historical electronic medical record data of more than 7,300 patients with type 2 diabetes and concluded
that there is a pervasiveness of clinical inertia for the management of type 2 diabetes in real-world clinical practice settings.
The
selected patients had an A1C value of ≥ 7% on a stable regimen of two oral anti-diabetic agents for at least 6 months (from
2005 to 2016). The median time to treatment intensification after A1C was above target was longer than one year. For patients with an
A1C of ≥ 9%, therapy was not intensified in 44% of patients.
According
to lead study author Dr. Kevin Pantalone of Cleveland Clinic’s Endocrinology & Metabolism Institute, “Short of a patient
reporting non-adherence to their existing regimen of diabetes therapies, it is hard to imagine a reason why treatment intensification
was not observed more frequently, when indicated, particularly in patients with an A1C ≥ 9%. In general, if intensification
does not occur, the A1C can be expected to stay the same or get worse, it is not magically going to get better”.
(emphasis added)
ALRT Diabetes Solution
ALR
Technologies Inc. has created the Diabetes Solution to address the diabetes marketplace globally. The Company’s Diabetes Solution
consists of hardware, software and diabetes test supplies. We designed the Diabetes Solution to be focused on the HCP and is agnostic
and proactive. Our software operates on iOS, Android, Windows and MacOS systems. Enrollment into the ALRT Diabetes Solution will include
a branded glucometer, diabetes test strips, lancets and a carrying case. Our technology collects all the blood glucose data from the
glucometers, uploads it to a secure account and ships diabetes test strips as required. The patient data is aggregated to a predictive
A1C value for a comprehensive view of the treatment plan and patient adherence to the plan, with the data available (and messaged) to
authorized people.
The
ALRT Diabetes Solution addresses the five causes for not controlling diabetes with:
|
·
|
Active
patient monitoring;
|
|
·
|
Machine
intelligent data processing;
|
|
·
|
Insulin
dosage adjustment.
|
Active Patient Monitoring
Industry
data indicates that 50% or more of people on medications do not take them as prescribed, and that this non-compliance contributes to
10% of hospitalizations and billions of dollars spent annually in excessive and preventable healthcare costs. Reminding a person to take
an action is the first step in our system; monitoring their actions and their data is the second, and intervention when needed is the
important follow-up.
The
ALRT System monitors patient uploads and the underlying data providing more timely access to patient blood glucose data. Our system initiates
interventions by notifying the HCP of out-of-range results, or failure to upload data in accordance with the requirements of the care
plan. The ALRT System does not rely upon the patient for uploading data. The ALRT Diabetes Solution provides the notifications and audit
trail needed for achieving best practice results. Its performance tracking allows care teams to identify areas in treatment plans that
require change of improvement.
Direct Meter Uploads
Data
is uploaded via Bluetooth directly from the glucometer into the ALRT application. This ensures that the data is accurate and reliable
based on the results of testing.
Machine Intelligent Data Processing
Our
machine intelligence processes large amounts of data, notifies relevant stakeholders and flags patients for review making collaboration
real time. Across segments and populations, this also provides significant data points on use of diabetes test strips and insulin, which
may be significant for businesses in those industries.
Predicative
A1C
Included
in the Diabetes Solution is Predictive A1C. Predictive A1C is a patent-pending unique feature for monitoring the effectiveness of care
plans. This technology utilizes data diagnostics to compare targeted A1C with indicated results. Weekly patient blood glucose data is
evaluated, and HCPs are notified as needed for care plan review when blood glucose values exceed parameters set by the HCPs. Our platform
provides HCPs with patient prioritization reports and alerts based on the Predictive A1C measures and other related diagnostics. Predictive
A1C was designed to assist HCPs in addressing clinical inertia in diabetes care.
Insulin Dose
Adjustment
Included
in the Diabetes Solution is Insulin Dose Adjustment. IDA is an FDA-cleared feature that makes optimal insulin adjustment suggestions
to HCPs based on dosing guidelines from organizations like the ADA. This ensures that HCPs are making timely insulin dosage assessments
based on the blood testing results uploaded. ALRT’s next phase of technology advancement will produce an algorithm for advancing
non-insulin diabetes therapies according to clinical practice guidelines.
Evolution of
the Diabetes Solution
In
August 2010, the Company received the results of a clinical trial conducted by Dr. Hugh Tildesley using the ALRT Health-e-Connect System,
which was an earlier version of the Diabetes Solution. The trial showed A1C dropping from 8.8% to 7.6% for the Intervention Group using
ALRT’s Health-e-Connect System as part of a diabetes management
program. The A1C test is important in diabetes treatment management as a long-term measure of control over blood glucose for diabetes
patients. According to the Center for Disease Control and Prevention, “In general, every percentage drop in A1C blood test results
(e.g., from 8% to 7%), can reduce the risk of microvascular complications (eye, kidney and nerve diseases) by 40%”. The trial served
as the basis for an article titled Effect of Internet Therapeutic Intervention on A1C Levels in Patients with Type 2 Diabetes Treated
with Insulin, which was published in the August 2010 Diabetes Care publication.
In
July 2011, the follow-up results of the Dr. Tildesley clinical trial were published in the Canadian Journal of Diabetes. Dr. Tildesley
conducted a 12-month study using Health-e-Connect System as an IBGMS to provide intensive blood glucose control to determine the effects
of internet-based blood glucose monitoring on A1C levels in patients with type 2 diabetes treated with insulin. Dr. Tildesley concluded
that, “While IBGMS intervention was not a substitute for the patient–physician interaction in a clinical setting, it significantly
improved A1C and, over time, we observed better glycemic control and patient satisfaction”.
In
October 2011, the Company received 510(k) clearance from the FDA for remote monitoring of patients in support of effective diabetes management
programs. The 510(k) clearance enabled the Company to commence with the United States marketing and sales launch of its Health-e-Connect
System. The Health-e-Connect System has since evolved to be part of the ALRT Diabetes System.
In
September 2014, the Company initiated its pilot program with one of the Kansas City Metropolitan Physician Association (“KCMPA”)
clinics to deploy its Diabetes Solution. Data from the KCMPA pilot program indicated that a number of patients had achieved reductions
in their A1C levels. Furthermore, the data indicated that patients that left the pilot program had increases in A1C subsequent.
On
February 18, 2015, the Company filed a 510(k) application with the FDA to add a remote insulin dosing recommendation feature to the Company’s
Diabetes Solution. The Company utilized the publicly available algorithm of the American Association for Clinical Endocrinologists (“AACE”)
and ADA. This feature allows the Company to regularly run a patient’s blood glucose data (and other key data) through the AACE
and ADA algorithm. When the algorithm indicates that the patient’s dose may not be optimal, the Diabetes Solution would provide
the HCP that a dose change may be warranted and what the change would be based on AACE and ADA guidelines. The decision about the dose
change would rest entirely with the HCP. However, this new feature may make a significant contribution to improving the outcomes of diabetes
patients if it allowed HCPs to keep their patients at the optimal dose for longer periods. On September 18, 2017, the Company received
clearance from the FDA for its IDA feature within the Company’s Diabetes Solution.
On
June 20, 2017, the Company’s Chief Executive Officer filed a worldwide patent application under the Patent Cooperation Treaty to
the World Intellectual Property Organization for the Predictive A1C feature. The Company holds the rights to use the Predictive A1C feature.
During 2019, the Company and the Chairman have entered into the National Phase for the applications by applying to target member countries.
During
2019, the Company added automated patient management to the Diabetes Solution. The Company is also seeking to have a private label glucometer,
diabetes test strips, lancets and carrying cases produced as part of the Diabetes Solution. The Company is in talks with a manufacturer
that has global operations.
During
2019, the Company initiated support for CGMS with the ALRT Diabetes Solution. CGM has become the standard of care for patients with type
1 diabetes and is quickly gaining favor with type 2 diabetes patients who use insulin.
ALRT Pre-Diabetes
System
A
prevention-based feature of the Diabetes Solution, the ALRT Prediabetes System has been designed in direct response to discussions with
government healthcare authorities for a scalable solution to the growing problem of prediabetes. The Prediabetes Solution provides patients
with educational videos and supplemental content formatted for mobile devices and a private online community to discuss disease management
(e.g., support, weight loss, diet, etc.). Most importantly, the System tracks patients and reminds them to test their A1C according to
payer protocols.
ALR GluCurve
for Pets
ALR
Technologies Inc. has developed the GluCurve Pet CGM to address an unmet need in diabetes care for felines and canines by combining the
hardware of a CGM with the software of an adapted version of its Diabetes Solution platform for use by veterinarians in animal health.
The
GluCurve Pet CGM platform allows the blood glucose readings from the medical device placed on the pet to be uploaded to the cloud where
the data is processed and converted into daily glucose curve graphs and data sets that can be reviewed and compared by the veterinarian
at any time. The system provides the doctor with insulin dose calculators and recommendations based on current clinical practice guidelines.
The
current method to monitor glucose levels in diabetic felines and canines is to prepare an in-clinic glucose curve which consists of the
following steps:
|
1)
|
the
pet is dropped off at a veterinary clinic
|
|
2)
|
the
pet is given an insulin shot.
|
|
3)
|
The
clinic staff will draw blood every 2 hours for 10-12 hours, performing the following steps
each time
|
|
a.
|
test
the blood in a blood glucose meter
|
|
c.
|
plot
the data into a graph
|
|
d.
|
assess
the effectiveness of the insulin dose and glycemic control
|
|
4)
|
the
pet is picked up by their owner.
|
The
GluCurve Pet CGM solves the multiple issues that arise from doing an in-clinic glucose curve:
|
·
|
Manual
process of data collection, review, and analysis
|
|
·
|
Burden
on the clinic staff and the pet owner
|
Inaccurate
Data
A
CGM is placed on the pet by the veterinarian in minutes and the pet is sent home where the glucose readings will be automatically taken
and uploaded for up to 14 days which eliminates the stress on the animal from being housed in the clinic and from getting its blood drawn
which can elevate glucose levels. A CGM also provides readings every 5 minutes which gives better insight to the veterinarian of the
highs and lows of the pet’s glucose levels throughout the day which are often missed when only checking every 2 hours during an
in-clinic glucose curve.
Manual
Process of Data Collection, Review and Analysis
A
CGM automatically uploads 288 glucose readings per day to the ALRT cloud where the data is analyzed, organized, then displayed on the
platform for the veterinarian to view. The GluCurve Pet CGM platform provides patient management of diabetic pets so historical data
can also be reviewed and compared.
Burden
on Clinic Staff and Pet Owner
A
CGM is placed on the pet in minutes, after which they are sent home, greatly reducing the time spent by the staff during an in-clinic
glucose curve of caring for the pet and manually drawing blood and recording readings every 2 hours. The platform also greatly
reduces the time needed by the doctor to review and make insulin dose adjustments by offering dosing calculators, guidelines, and decision
flowcharts based on current clinical practice guidelines.
Results of Operations
Six
months ended June 30, 2021 compared to Six months ended June 30, 2020
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
|
Amount ($)
Increase /
(Decrease)
|
|
Percentage (%) Increase / (Decrease)
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product development costs
|
|
$
|
240,000
|
|
|
|
218,000
|
|
|
|
22,000
|
|
|
|
10
|
|
Professional fees
|
|
|
356,000
|
|
|
|
467,000
|
|
|
|
(111,000
|
)
|
|
|
(24
|
)
|
Selling, general and administrative
|
|
|
424,000
|
|
|
|
254,000
|
|
|
|
170,000
|
|
|
|
67
|
|
|
|
|
1,020,000
|
|
|
|
939,000
|
|
|
|
81,000
|
|
|
|
9
|
|
Other Items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
2,284,000
|
|
|
|
1,044,000
|
|
|
|
1,240,000
|
|
|
|
119
|
|
Loss on settlement of debt
|
|
|
33,000
|
|
|
|
—
|
|
|
|
33,000
|
|
|
|
100
|
|
Net Loss
|
|
$
|
3,337,000
|
|
|
|
1,983,000
|
|
|
|
1,354,000
|
|
|
|
68
|
|
The
net loss for the six months ended June 30, 2021 was 68% ($1,354,000) higher than the net loss at June 30, 2020. Loss before
other items and stock-based compensation was $351,000 (66%) higher during the six months ended June 30, 2021, as compared to the
six months ended June 30, 2020. We highlight that loss before other items and stock-based compensation is a “non-GAAP
financial measure”. This measure is calculated by removing those items from the net loss presented on our unaudited condensed consolidated
statements of operations. This measure does not have a standardized meaning under U.S. GAAP. Management uses this measure internally
to evaluate its results of operations as it removes the impact of stock-based compensation, non-operational losses and interest accretion.
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
|
Amount ($)
Increase /
(Decrease)
|
|
Percentage (%) Increase / (Decrease)
|
|
|
|
|
|
|
|
|
|
Loss Before Other Items
|
|
$
|
1,020,000
|
|
|
|
939,000
|
|
|
|
81,000
|
|
|
|
9
|
|
Stock-based compensation included in selling, general and administrative expense, professional fees and product development costs
|
|
|
141,000
|
|
|
|
411,000
|
|
|
|
(270,000
|
)
|
|
|
(66
|
)
|
Loss Before Other Items and Stock-based Compensation
|
|
$
|
879,000
|
|
|
|
528,000
|
|
|
|
351,000
|
|
|
|
66
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
net loss before interest and stock-based compensation for the Company’s six months ended June 30, 2021 increased due to increased
professional and personnel costs. Professional fees before the additional of related stock-based compensation was $313,000 for the six
months ended June 30, 2021 as compared to $75,000 for the six months ended June 30, 2020, an increase of $238,000 (317%).
|
·
|
The
Company incurred increased professional costs related to assessing business structure alternatives.
|
|
·
|
The
Company has retained additional personnel to support commercialization strategies in Singapore
and the United States, and
|
|
·
|
The
Company has retained additional personnel related to evaluating and forming its pet division.
|
General
and Administrative
General
and administrative costs incurred consist of salaries and consulting fees of management personnel, stock-based compensation for options
granted to management personnel, travel and trade show costs, rent of the Company’s corporate office, website development costs
and general costs incurred through day-to-day operations.
Results of Operations
(continued)
During
the period, the Company had an increase in selling, general and administrative expenses, primarily driven by an increase in salaries
and consulting fees paid to personnel and to a market research firm related to commercialization plans for the Company’s Diabetes
Solution. The components of general and administrative expenses and the changes therein can be seen as follows:
Selling, General and Administrative:
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
|
Amount ($)
Increase /
(Decrease)
|
Salaries and consulting fees
|
|
$
|
305,000
|
|
|
|
185,000
|
|
|
|
120,000
|
|
Travel and trade shows
|
|
|
10,000
|
|
|
|
14,000
|
|
|
|
(4,000
|
)
|
Website and information technology
|
|
|
9,000
|
|
|
|
18,000
|
|
|
|
(9,000
|
)
|
Transfer agent, filing fees and quotation costs
|
|
|
8,000
|
|
|
|
22,000
|
|
|
|
(14,000
|
)
|
Market research consulting fees
|
|
|
44,000
|
|
|
|
—
|
|
|
|
44,000
|
|
License and permits
|
|
|
10,000
|
|
|
|
7,000
|
|
|
|
3,000
|
|
Other general and administrative costs
|
|
|
38,000
|
|
|
|
8,000
|
|
|
|
30,000
|
|
Total
|
|
$
|
424,000
|
|
|
|
254,000
|
|
|
|
170,000
|
|
During
Q2 2021, the Company had increased general and administrative operating expenses, as compared to the same period in 2020. The cash-based
general and administrative expenses increased by $170,000 during Q2 2021, as compared to Q1 2020 which was primarily related to increased
personnel costs and market research consulting fees.
Product
development costs
Substantially
all of the product development costs incurred related to a) services provided by contractors of the Company, and b) expenses incurred
for product development. The change in balance from the previous year relates primarily to changes in composition of our technical team
in the current year, as compared to the previous year. The Company incurred stock-based compensation expense of $98,000 during Q2 2021
related to the grant and vesting of options to its product development team compared to $19,000 during Q2 2020.
Professional
fees
Professional
costs incurred consist of consulting and advisory fees of certain professionals retained, audit fees, tax consultant fees, recruiter
fees, legal fees and stock-based compensation for options granted to professionals. During the period, there was a significant increase
in professional fees related to:
|
·
|
The
recruitment of certain personnel;
|
|
·
|
The
engagement of additional accounting personnel, and
|
|
·
|
Legal
and tax advice obtained related to corporate structure analysis.
|
By
type of professional cost, the variance can be seen as follows:
Professional fees:
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
|
Amount ($)
Increase /
(Decrease)
|
Corporate auditor
|
|
$
|
14,000
|
|
|
|
16,000
|
|
|
|
(2,000
|
)
|
Accounting fees
|
|
|
76,000
|
|
|
|
32,000
|
|
|
|
44,000
|
|
Tax consultant fees
|
|
|
40,000
|
|
|
|
—
|
|
|
|
40,000
|
|
Legal fees
|
|
|
90,000
|
|
|
|
17,000
|
|
|
|
73,000
|
|
Recruiter fees
|
|
|
48,000
|
|
|
|
—
|
|
|
|
48,000
|
|
Professionals retained
|
|
|
45,000
|
|
|
|
10,000
|
|
|
|
35,000
|
|
Stock-based compensation
|
|
|
43,000
|
|
|
|
392,000
|
|
|
|
(349,000
|
)
|
Total
|
|
$
|
356,000
|
|
|
|
467,000
|
|
|
|
(111,000
|
)
|
Excluding
the difference in net loss attributed to the grant of stock options in the prior year, professional fees increased by $238,000 from the
comparative period of the prior year.
Results of Operations
(continued)
Interest
expense
Interest
expense was from the following sources for the six months ended June 30, 2021 and 2020:
Interest expense:
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
|
Amount ($)
Increase /
(Decrease)
|
Interest expense incurred on promissory notes
|
|
$
|
264,000
|
|
|
|
264,000
|
|
|
|
—
|
|
Interest expense incurred on lines of credit
|
|
|
671,000
|
|
|
|
719,000
|
|
|
|
(48,000
|
)
|
Interest expense incurred on stock options modified
|
|
|
1,288,000
|
|
|
|
—
|
|
|
|
1,288,000
|
|
Imputed interest on zero interest loans
|
|
|
60,000
|
|
|
|
62,000
|
|
|
|
(2,000
|
)
|
Other interest
|
|
|
1,000
|
|
|
|
—
|
|
|
|
1,000
|
|
Total
|
|
$
|
2,284,000
|
|
|
|
1,045,000
|
|
|
|
1,239,000
|
|
Interest
on Promissory Notes
On
May 10, 2021, the Company issued 2,000,000 shares of common stock with a fair market price of $0.057 to a creditor to extinguish $20,000
in promissory notes and $3,000 in accrued interest on promissory notes. There were no other significant changes in the amount of promissory
notes outstanding as at June 30, 2021 and 2020. The interest incurred on promissory notes was consistent during the six months ended
June 30, 2021 and 2020.
Interest
on Lines of Credit
The
Company has two line of credit facilities with balances as follows:
Lines of credit:
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
|
Amount ($)
Increase /
(Decrease)
|
Line of credit provided by Sidney Chan
|
|
$
|
9,941,000
|
|
|
|
10,201,000
|
|
|
|
(260,000
|
)
|
Line of credit provided by Christine Kan
|
|
|
2,000,000
|
|
|
|
2,000,000
|
|
|
|
—
|
|
Total
|
|
$
|
11,941,000
|
|
|
|
12,201,000
|
|
|
|
(260,000
|
)
|
The
principal balance of the line of credit due to Mr. Sidney Chan decreased as principal of $1,038,967 was retired through the issuance
of shares on September 21, 2020. This decrease was offset by advances to Mr. Chan under the line of credit to finance the operations
of the Company.
The
Company incurred interest on the lines of credit as follows:
Interest expense on lines of credit:
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
|
Amount ($)
Increase /
(Decrease)
|
Interest expense incurred on the line of credit from Sidney Chan during the period
|
|
$
|
551,000
|
|
|
|
599,000
|
|
|
|
(48,000
|
)
|
Interest expense incurred on the line of credit from Christine Kan during the period
|
|
|
120,000
|
|
|
|
120,000
|
|
|
|
—
|
|
Total
|
|
$
|
671,000
|
|
|
|
719,000
|
|
|
|
(48,000
|
)
|
Imputed
Interest
During
the 2021 and 2020 periods, the Company had certain zero interest promissory notes and accounts payable in excess of one year. Pursuant
to the Company’s accounting policy, these zero interest amounts are considered to be financing items in nature and are assigned
a deemed interest rate (1% per month). The interest incurred on these is expensed as imputed interest and instead of increasing the liabilities
of the Company, it is allocated to equity under the financial statement line item additional paid-in capital. The change from
the prior period is related to the discussion included under Interest on Promissory Notes above.
Liquidity and
Capital Resources
Working Capital
|
|
As At
June 30,
2021
|
|
As At
December 31, 2020
|
|
Amount ($)
Increase /
(Decrease)
|
|
Percentage (%) Increase / (Decrease)
|
Current Assets
|
|
$
|
434,000
|
|
|
|
129,000
|
|
|
|
305,000
|
|
|
|
236
|
|
Current Liabilities
|
|
|
22,655,000
|
|
|
|
21,889,000
|
|
|
|
766,000
|
|
|
|
3
|
|
Working Capital Deficiency
|
|
$
|
(22,221,000
|
)
|
|
|
(21,760,000
|
)
|
|
|
(461,000
|
)
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
Company has a severe working capital deficiency. It does not have the ability to service its current liabilities for the next twelve
months and is reliant on its line of credit facilities to meet its ongoing operations. Until the Company has revenue-producing activities
that exceed its operating requirements, it will be unable to service its current liabilities and the working capital deficit will continue
to increase. As of the date of this report, the Company has not commenced revenue-generating activities. The Company is expecting to
generate revenues in Singapore during the 2021 fiscal year; however, the amount and timing are uncertain. The revenues generated in 2021
are not expected to be sufficient to finance the ongoing operations of the business and repay the current liabilities. The Company is
seeking to complete its Rights Offering that would provide additional financing of $5,051,000, which is significantly less than the current
liabilities outstanding. There is substantial doubt about the Company’s ability to repay its current liabilities in the near term
or any time in the future, which could ultimately lead to business failure.
Current Assets
The
Company’s nominal current assets as at June 30, 2021 and December 31, 2020 consist of cash and prepaid expenses.
Current Liabilities
The
Company has current liabilities of $22,655,000 at June 30, 2021, as compared to $21,889,000 at December 31, 2020. Current liabilities
are as follows:
|
|
June 30,
2021
|
|
December 31, 2020
|
|
Change
($)
|
|
Change
(%)
|
Accounts payable and accrued liabilities
|
|
$
|
937,000
|
|
|
|
1,114,000
|
|
|
|
(177,000
|
)
|
|
|
(16
|
)
|
Promissory notes to related parties
|
|
|
3,032,000
|
|
|
|
3,032,000
|
|
|
|
—
|
|
|
|
—
|
|
Promissory notes to arm’s length parties
|
|
|
2,223,000
|
|
|
|
2,254,000
|
|
|
|
(31,000
|
)
|
|
|
(1
|
)
|
Interest payable
|
|
|
3,847,000
|
|
|
|
3,575,000
|
|
|
|
272,000
|
|
|
|
8
|
|
Lines of credit from related parties
|
|
|
12,616,000
|
|
|
|
11,914,000
|
|
|
|
702,000
|
|
|
|
6
|
|
Total current liabilities
|
|
$
|
22,655,000
|
|
|
|
21,889,000
|
|
|
|
766,000
|
|
|
|
3
|
|
The
fluctuations in accounts payable occurred in the regular course of business.
The
increase in interest payable relates to $264,000 of accrued interest incurred on promissory notes at their stated rates of interest,
$11,000 relates to the reclassification from promissory notes to arm’s length parties to interest payable and $3,000 was extinguished
as a result of shares of common stock issued. All of the promissory notes and related interest payable are overdue.
The
increase in the lines of credit payable of $702,000 is attributable to borrowings of:
|
·
|
$403,000
to fund operations, product development activities, overhead, and its sales and marketing
program;
|
|
·
|
$371,000
of interest repayment toward interest payable; and
|
|
·
|
$670,000
of unpaid interest incurred on the principal of the borrowed amounts.
|
Cash Flows
Cash Flows
|
|
Six Months Ended
June 30, 2021
|
|
Six Months Ended
June 30, 2020
|
Cash flows used in Operating Activities
|
|
$
|
(857,000
|
)
|
|
$
|
(443,000
|
)
|
Cash flows provided by Financing Activities
|
|
|
1,167,000
|
|
|
|
442,000
|
|
Net Increase (Decrease) in Cash During Period
|
|
$
|
310,000
|
|
|
$
|
(1,000
|
)
|
Cash Balances
As
of June 30, 2021, the Company’s cash balance was $376,639 compared to $66,190 as of December 31, 2020.
Cash Used in
Operating Activities
Cash
used by the Company in operating activities during the six-month period ended June 30, 2021 was $858,000 in comparison with $443,000
used during the same period last year. The Company’s expenditures from operations were used as follows (approximate amounts):
Cash Used in Operating Activities Reconciliation
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
Net loss
|
|
$
|
(3,337,000
|
)
|
|
$
|
(1,983,000
|
)
|
Stock-based compensation incurred for product development, professional fees and interest expense
|
|
|
1,429,000
|
|
|
|
411,000
|
|
Non-cash imputed interest expense
|
|
|
60,000
|
|
|
|
61,000
|
|
Loss on debt settlement
|
|
|
33,000
|
|
|
|
—
|
|
Net purchases with balances owing in accounts payable and accrued liabilities
|
|
|
18,000
|
|
|
|
84,000
|
|
Retainers and prepaid services
|
|
|
5,000
|
|
|
|
—
|
|
Accrued interest on lines of credit
|
|
|
671,000
|
|
|
|
719,000
|
|
Accrued interest from promissory notes
|
|
|
264,000
|
|
|
|
265,000
|
|
Cash used in operating activities
|
|
$
|
(857,000
|
)
|
|
$
|
(443,000
|
)
|
|
|
|
|
|
|
|
|
|
The
expenditures incurred were to fund the operating activities of the business.
Cash Proceeds
from Financing Activities
Cash
sourced by the Company from financing activities during the six months ended June 30, 2021 was $1,167,000 in comparison with $442,000
sourced during the same period last year. The funds were sourced as follows:
Cash from Financing Activities Reconciliation
|
|
Six Months Ended
June 30,
2021
|
|
Six Months Ended
June 30,
2020
|
Proceeds from Rights Offering
|
|
$
|
1,125,000
|
|
|
$
|
—
|
|
Proceeds from exercise of options
|
|
|
12,000
|
|
|
|
—
|
|
Net proceeds from line of credit from Mr. Sidney Chan
|
|
|
30,000
|
|
|
|
442,000
|
|
Cash provided by financing activities
|
|
$
|
1,167,000
|
|
|
$
|
442,000
|
|
Short- and
Long-term Liquidity
As
of June 30, 2021, the Company does not have the current financial resources and committed financing to enable it to meet its administrative
overhead, product development budgeted costs and debt obligations over the next 12 months.
All
of the Company’s debt financing is due on demand or overdue. The Company will seek to obtain creditors’ consents to delay
repayment of these loans until it is able to replace these financings with funds generated by operations, replacement debt, or from equity
financings through private placements or the exercise of options and warrants. While the Company is seeking to complete its Rights Offering,
there is no certainty that it will be able to do so. If the Company is not able to complete the Rights Offering, it will not have sufficient
funds to repay the debt financing past maturity and it will be due on demand. While the Company’s creditors have agreed to extend
repayment deadlines in the past, there is no assurance that they will continue to do so in the future. The Company has faced litigation
from creditors in the past and is currently being sued by one creditor. There is no assurance that additional creditors will not make
claims against the Company in the future. Failure to obtain either replacement financing or creditor consent to delay the repayment of
existing financing could result in the Company having to cease operations.
Tabular Disclosure of Contractual Obligations:
|
|
Payments Due by Period
|
|
|
Total
|
|
Less
Than 1
Year
|
|
1-3
Years
|
|
3-5
Years
|
|
More
Than 5
Years
|
Accounts payable and accrued liabilities
|
|
$
|
937,000
|
|
|
$
|
937,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Promissory notes to related parties
|
|
|
3,032,000
|
|
|
|
3,032,000
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Promissory notes to arm’s length parties
|
|
|
2,223,000
|
|
|
|
2,223,000
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Interest payable
|
|
|
3,847,000
|
|
|
|
3,847,000
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Lines of credit
|
|
|
12,616,000
|
|
|
|
12,616,000
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
$
|
22,655,000
|
|
|
$
|
22,655,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
The
Company will continue to use the funds available from the lines of credit to cover administrative overhead and product development requirements
until such time it can establish cash flows from operations. In the next six months, the Company anticipates the amount borrowed from
the lines of credit to increase compared to the past six months, as it expects to commercially launch its Diabetes Management System
before December 31, 2021.
Critical Accounting Policies and
Going Concern
Our
discussion and analysis of our results of operations and liquidity and capital resources are based on our unaudited condensed consolidated
financial statements for the six months ended June 30, 2021 and 2020, which have been prepared in accordance with U.S. GAAP.
The
preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities. We base our estimates on
historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including
assumptions as to future events. These estimates form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. By their nature, estimates are subject to an inherent degree of uncertainty. Actual
results may differ materially from our estimates.
The
Company’s condensed consolidated financial statements have been prepared on a going concern basis, which presumes the realization
of assets and the discharge of liabilities and commitments in the normal course of operations for the foreseeable future. See note 1
of the unaudited condensed consolidated financial statements.
Due
to our being a development stage company and not having generated significant revenues, in the notes to our condensed consolidated financial
statements, we have included disclosure regarding concerns about our ability to continue as a going concern.
Off-Balance
Sheet Arrangements
The
Company has no off-balance sheet financing arrangements that have or are reasonably likely to have a current or future effect on the
Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources, that is material to investors.